Psoriasis drug market set to see strong growth until 2018, reaching a value of $6.7 million

The psoriasis therapeutics market is forecast to show high growth until 2018 and market research firm GlobalData estimates that the sector was worth $3.6 billion in 2010 and expects it to grow at a compound annual growth rate (CAGR) of 8.1% to reach $6.7 billion by 2018.

This high growth forecast is primarily attributed to the currently approved drugs reaching their peak sales and the launch of first-in-class molecules during the forecast period.

For patients with moderate to severe psoriasis, the current treatment options offer reasonable clinical outcomes. Nevertheless, standard treatments are associated with long-term toxicity, side effects, and inconvenience. Therefore, the global psoriasis therapeutics market is attractive, with a high unmet need for a cure of the underlying cause of the disease. This unmet need in the market is high for topical and conventional systemic therapy and moderate for biologics. The unmet need arises due to the moderate efficacy and safety profile of the marketed drugs.